140 related articles for article (PubMed ID: 38492433)
1. Barriers and advocacy needs for hepatitis C services in prisons: Informing the prisons hepatitis C advocacy toolkit.
Walker SJ; Shrestha LB; Lloyd AR; Dawson O; Sheehan Y; Sheehan J; Maduka NBC; Cabezas J; Akiyama MJ; Kronfli N;
Int J Drug Policy; 2024 Apr; 126():104386. PubMed ID: 38492433
[TBL] [Abstract][Full Text] [Related]
2. Considering treatment-as-prevention scale-up for Australian prisons: a qualitative sub-study of expert stakeholders from the Australian 'surveillance and treatment of prisoners with hepatitis C' project (SToP-C).
Rance J; Lafferty L; Treloar C;
Harm Reduct J; 2021 Apr; 18(1):46. PubMed ID: 33902595
[TBL] [Abstract][Full Text] [Related]
3. A 'one-stop-shop' point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: The PIVOT study.
Sheehan Y; Cunningham EB; Cochrane A; Byrne M; Brown T; McGrath C; Lafferty L; Tedla N; Dore GJ; Lloyd AR; Grebely J
J Hepatol; 2023 Sep; 79(3):635-644. PubMed ID: 37116714
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C elimination among people incarcerated in prisons: challenges and recommendations for action within a health systems framework.
Akiyama MJ; Kronfli N; Cabezas J; Sheehan Y; Thurairajah PH; Lines R; Lloyd AR;
Lancet Gastroenterol Hepatol; 2021 May; 6(5):391-400. PubMed ID: 33857445
[TBL] [Abstract][Full Text] [Related]
5. Offering HCV treatment to prisoners is an important opportunity: key principles based on policy and practice assessment in Europe.
Stöver H; Meroueh F; Marco A; Keppler K; Saiz de la Hoya P; Littlewood R; Wright N; Nava F; Alam F; Walcher S; Somaini L
BMC Public Health; 2019 Jan; 19(1):30. PubMed ID: 30621658
[TBL] [Abstract][Full Text] [Related]
6. Barriers and facilitators to hepatitis C (HCV) screening and treatment-a description of prisoners' perspective.
Crowley D; Van Hout MC; Lambert JS; Kelly E; Murphy C; Cullen W
Harm Reduct J; 2018 Dec; 15(1):62. PubMed ID: 30538000
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C virus screening and treatment in Irish prisons from a governor and prison officer perspective - a qualitative exploration.
Crowley D; Van Hout MC; Murphy C; Kelly E; Lambert JS; Cullen W
Health Justice; 2018 Dec; 6(1):23. PubMed ID: 30569249
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C in Australian prisons: a national needs assessment.
Mina MM; Herawati L; Butler T; Lloyd A
Int J Prison Health; 2016; 12(1):3-16. PubMed ID: 26933988
[TBL] [Abstract][Full Text] [Related]
9. Competing priorities and second chances - A qualitative exploration of prisoners' journeys through the Hepatitis C continuum of care.
Crowley D; Cullen W; Lambert JS; Van Hout MC
PLoS One; 2019; 14(9):e0222186. PubMed ID: 31509571
[TBL] [Abstract][Full Text] [Related]
10. Consensus recommendations on the management of hepatitis C in Australia's prisons.
Winter RJ; Sheehan Y; Papaluca T; Macdonald GA; Rowland J; Colman A; Stoove M; Lloyd AR; Thompson AJ
Med J Aust; 2023 Mar; 218(5):231-237. PubMed ID: 36871200
[TBL] [Abstract][Full Text] [Related]
11. Incidence and correlates of hepatitis C virus infection in a large cohort of prisoners who have injected drugs.
Snow KJ; Young JT; Preen DB; Lennox NG; Kinner SA
BMC Public Health; 2014 Aug; 14():830. PubMed ID: 25113132
[TBL] [Abstract][Full Text] [Related]
12. Combined treatment and prevention strategies for hepatitis C virus elimination in the prisons in New South Wales: a modelling study.
Bretaña NA; Gray RR; Cunningham EB; Betz-Stablein B; Ribeiro R; Graw F; Luciani F; Lloyd AR
Addiction; 2020 May; 115(5):901-913. PubMed ID: 31633853
[TBL] [Abstract][Full Text] [Related]
13. Identifying barriers and enablers to opt-out hepatitis C virus screening in provincial prisons in Quebec, Canada: A multilevel, multi-theory informed qualitative study with correctional and healthcare professional stakeholders.
Ruiz AS; Fontaine G; Patey AM; Grimshaw JM; Presseau J; Cox J; Dussault C; Kronfli N
Int J Drug Policy; 2022 Nov; 109():103837. PubMed ID: 36030569
[TBL] [Abstract][Full Text] [Related]
14. The furthest left behind: the urgent need to scale up harm reduction in prisons.
Sander G; Murphy F
Int J Prison Health; 2017 Sep; 13(3-4):185-191. PubMed ID: 28914120
[TBL] [Abstract][Full Text] [Related]
15. Harm reduction and viral hepatitis C in European prisons: a cross-sectional survey of 25 countries.
Bielen R; Stumo SR; Halford R; Werling K; Reic T; Stöver H; Robaeys G; Lazarus JV
Harm Reduct J; 2018 May; 15(1):25. PubMed ID: 29751763
[TBL] [Abstract][Full Text] [Related]
16. Palliative and end-of-life care in prisons: a content analysis of the literature.
Maschi T; Marmo S; Han J
Int J Prison Health; 2014; 10(3):172-97. PubMed ID: 25764177
[TBL] [Abstract][Full Text] [Related]
17. Testing for hepatitis C virus infection in UK prisons: What actually happens?
Jack K; Thomson BJ; Irving WL
J Viral Hepat; 2019 Jun; 26(6):644-654. PubMed ID: 30702194
[TBL] [Abstract][Full Text] [Related]
18. "You need a designated officer" - Recommendations from correctional and justice health personnel for scaling up hepatitis C treatment-as-prevention in the prison setting.
Lafferty L; Rance J; Byrne M; Milat A; Dore GJ; Grebely J; Lloyd AR; Treloar C;
Int J Drug Policy; 2022 Aug; 106():103746. PubMed ID: 35636069
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis C in European prisons: a call for an evidence-informed response.
Arain A; Robaeys G; Stöver H
BMC Infect Dis; 2014; 14 Suppl 6(Suppl 6):S17. PubMed ID: 25252822
[TBL] [Abstract][Full Text] [Related]
20. Reducing barriers to the hepatitis C care cascade in prison via point-of-care RNA testing: a qualitative exploration of men in prison using an integrated framework.
Lafferty L; Sheehan Y; Cochrane A; Grebely J; Lloyd AR; Treloar C
Addiction; 2023 Jun; 118(6):1153-1160. PubMed ID: 36683132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
